The European medicines regulator said on Friday it will review safety information for Eisai and Biogen's Leqembi, nearly ...

The "Alzheimer’s & Caregiving Educational Conference" will be held from 10 a.m. to 1 p.m. on Feb. 19 at the Hilton Jackson Hotel on 1001 East County Line Road. This free confere ...

Groundbreaking study uncovers the crucial link between REM sleep patterns and Alzheimer's disease, providing new insights for ...

Finally, a few studies in mice have found that the medications can reduce the buildup of the protein tau in the brain, which is a key contributor to Alzheimer’s disease. Scaling back tau buildup could ...

Taking too long to enter the phase of sleep in which we dream may be an early sign of Alzheimer's disease. This is the ...

SaveHealth provides an overview of Alzheimer's disease, including treatment and coping mechanisms for those with the disease ...

Delays in dreaming might be an early warning sign of Alzheimer's disease. People who take significantly longer to enter the ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

Taking longer to enter the dream phase can disrupt the ability to consolidate memories and interfere with emotion regulation.

A pathway once considered fundamental in Alzheimer’s disease is being studied intensely again, and may soon result in safer, ...

The reassessment of Leqembi’s safety data follows the agency’s previous recommendation of the drug for use in the EU.

European Union regulators will review new information relating to the safety of Eisai Co.’s and Biogen Inc.’s medicine for ...